Hypoxia signaling: Challenges and opportunities for cancer therapy

Hypoxia is arguably the first recognized cancer microenvironment hallmark and affects virtually all cellular populations present in tumors. During the past decades the complex adaptive cellular responses to oxygen deprivation have been largely elucidated, raising hope for new anti cancer agents. Des...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2022-10, Vol.85, p.185-195
Main Authors: Ivan, Mircea, Fishel, Melissa L., Tudoran, Oana M., Pollok, Karen E., Wu, Xue, Smith, Paul J.
Format: Article
Language:English
Subjects:
HIF inhibitors
HIF1
HIF2
Hypoxia
Hypoxia-activated prodrug
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypoxia is arguably the first recognized cancer microenvironment hallmark and affects virtually all cellular populations present in tumors. During the past decades the complex adaptive cellular responses to oxygen deprivation have been largely elucidated, raising hope for new anti cancer agents. Despite undeniable preclinical progress, therapeutic targeting of tumor hypoxia is yet to transition from bench to bedside. This review focuses on new pharmacological agents that exploit tumor hypoxia or interfere with hypoxia signaling and discusses strategies to maximize their therapeutic impact.
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2021.10.002